Drug Therapy Protocols:
Packed Red Blood Cells – Group O negative

Disclaimer and copyright
©2016 Queensland Government

All rights reserved. Without limiting the reservation of copyright, no person shall reproduce, store in a retrieval system or transmit in any form, or by any means, part or the whole of the Queensland Ambulance Service (‘QAS’) Clinical practice manual (‘CPM’) without the prior written permission of the Commissioner.

The QAS accepts no responsibility for any modification, redistribution or use of the CPM or any part thereof. The CPM is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents.

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome, please forward to: Clinical.Guidelines@ambulance.qld.gov.au

<table>
<thead>
<tr>
<th>Date</th>
<th>April, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to Packed Red Blood Cells – Group O negative administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to all QAS clinical staff.</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>April, 2019</td>
</tr>
<tr>
<td>Information security</td>
<td>This document has been security classified using the Queensland Government Information Security Classification Framework (QGISCF) as UNCLASSIFIED and will be managed according to the requirements of the QGISF.</td>
</tr>
</tbody>
</table>

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. 
Drug class
Haemoglobin replacement

Pharmacology
Packed red blood cells (PRBC) replace lost haemoglobin, aiming to improve oxygen carrying capacity of the blood and volume replacement.[1,2]

Metabolism
N/A

Indications
- Ongoing haemodynamic instability secondary to haemorrhage (following an appropriate volume resuscitation strategy)

Contraindications
- Non-consenting conscious patient (e.g. Jehovah Witness)

Precautions
- Previous transfusion reaction
- Immunosuppressed patients
- Hyperkalaemia

Side effects
- Acute haemolytic transfusion reaction
- Acute febrile transfusion reaction
- Anaphylaxis/allergic reactions
- Infection (bacterial, viral including low risk for HIV, Hep C and other blood borne viruses)
- Fluid overload
- Acute lung reaction
- Electrolyte imbalances
- Hypothermia
- Acidosis

Presentation
- 200–400 mL bag, Group O negative PRBC

<table>
<thead>
<tr>
<th>Onset (INF)</th>
<th>Duration (INF)</th>
<th>Half-life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate</td>
<td>Variable</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Special notes

- Each unit contains enough haemoglobin to raise the haemoglobin concentration in an average size adult by approximately 10 g/L.
- PRBC should be mixed thoroughly by gentle inversion before use and then transfused through an intravenous line approved for blood administration incorporating a standard 170 – 200 micrometre filter.
- Patients receiving transfusions shall be monitored for signs of the potential complications of transfusions and any suspected problems will be dealt with swiftly and efficiently. Severe reactions are most likely to occur within the first 15 minutes of the transfusion. If any reaction occurs cease infusion immediately and discuss with RSQ coordinator or QAS Clinical Consultation and Advice Line (as appropriate). Clinical presentation of transfusion reactions include: tachycardia, hypertension, fever, rigors, headache, myalgia, altered level of consciousness, bronchospasm, pulmonary oedema, and worsening coagulopathy.

Schedule

- Unscheduled.

Routes of administration

- Intravenous infusion (IV INF)
- Intravenous infusion (IO INF)

Special notes (cont.)

- Vital signs (temperature, pulse, respirations and blood pressure) shall be measured and recorded at the beginning and during each transfusion at a minimum of 15 minute intervals.
- The bag numbers of all PRBC transfusions administered to the patient must be documented on the e-ARF.
- All transfusion reactions must be immediately reported to the QAS on-call medical officer.
- All completed PRBC infusion bags are to be left with the medical/nursing staff at the receiving hospital.
- Informed consent for transfusion means a dialogue has occurred between the patient and the clinician. The significant risks, benefits and alternatives to transfusion, including the patient’s right to refuse the transfusion, will have been discussed. As a result of the discussion the patient should:
  - understand what medical action is recommended
  - be aware of the risks and benefits associated with the transfusion
  - appreciate the risks, and possible consequences of not receiving the recommended therapy
  - be given an opportunity to ask questions
  - give consent for the transfusion.
### Adult dosages

**Ongoing haemodynamic instability secondary to haemorrhage** (following an appropriate volume resuscitation strategy)

<table>
<thead>
<tr>
<th>Mode</th>
<th>Route</th>
<th>Information</th>
</tr>
</thead>
</table>
| **IV** | INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
**PRN** – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |
| **IO** | INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
**PRN** – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |

### Paediatric dosages

**Ongoing haemodynamic instability secondary to haemorrhage** (following an appropriate volume resuscitation strategy)

<table>
<thead>
<tr>
<th>Mode</th>
<th>Route</th>
<th>Information</th>
</tr>
</thead>
</table>
| **IV** | INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
**PRN** – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |
| **IO** | INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
**PRN** – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |